Amanda Kamar, MD
Pulmonary Disease · Chicago, ILNPI 1891291415
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Grifols USA, LLC at 55.8% of the total. Reporting peaked in 2024 at $2,632 and has fallen 92.0% since, to $211 in 2025.
Across 37 payments — averaging $108.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$2K
- Johnson & Johnson$491
- AstraZeneca$310
- Sanofi$237
- GSK$207
- Boston Scientific$190
- plus $342 from 8 others
What the payments were for
- Travel & lodging$1,55539%
- Food & beverage$2,39960%
- Education$702%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 10 | $2,246 |
| Johnson & Johnson | 7 | $491 |
| AstraZeneca | 3 | $310 |
| Sanofi | 2 | $237 |
| GSK | 3 | $207 |
| Boston Scientific | 2 | $190 |
| Boehringer Ingelheim | 2 | $114 |
| Jazz Pharmaceuticals Inc. | 1 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Melinta Therapeutics, LLC | 1 | $31 |
| Merck | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| AbbVie | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolastin-C Liquid$1,898
- XARELTO$242
- TEZSPIRE$125
- FASENRA$122
- Watchman$102
How this compares
$4,024 in reported general payments places this provider in the 65th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Chicago
- Douglas HogarthChicago$2.9M
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Ravi KalhanChicago$375K
- Brian GaribaldiChicago$356K
- Manu JainChicago$187K
- Richard WunderinkChicago$178K
- Rade TomicChicago$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.